Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) Director George M. Jenkins purchased 4,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were bought at an average cost of $12.93 per share, with a total value of $51,720.00. Following the acquisition, the director now directly owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This trade represents a 2.26 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Palvella Therapeutics Stock Performance
Shares of PVLA stock traded up $0.16 on Thursday, hitting $11.95. 9,752 shares of the stock traded hands, compared to its average volume of 46,083. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $22.32.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a report on Wednesday. They issued an “overweight” rating for the company.
Featured Stories
- Five stocks we like better than Palvella Therapeutics
- Retail Stocks Investing, Explained
- Micron Stock Under $100: Seize the AI-Driven Upside
- ESG Stocks, What Investors Should Know
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- How to Calculate Options Profits
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.